EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNHThe mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion’s infusion therapy Soliris, Share XEHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNHhttps://pharmaphorum.com/news/eha21-novartis-trumpets-iptacopan-as-oral-alternative-to-antibodies-in-pnh/
EHA21: Sanofi builds case for rare disease drug sutimlimab after FDA rejectionSanofi’s hopes of a speedy approval of first-in-class C1s inhibitor sutimlimab in rare disorder cold agglutinin disease (CAD) Share XEHA21: Sanofi builds case for rare disease drug sutimlimab after FDA rejectionhttps://pharmaphorum.com/news/eha21-sanofi-builds-case-for-rare-disease-drug-sutimlimab-after-fda-rejection/
BMS will file for earlier-line use of Breyanzi in lymphoma after trial winBristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but Share XBMS will file for earlier-line use of Breyanzi in lymphoma after trial winhttps://pharmaphorum.com/news/bms-will-file-for-earlier-line-use-of-breyanzi-in-lymphoma-after-trial-win/
Study links AstraZeneca COVID-19 shot to bleeding disorder ITPResearchers in Scotland have identified a possible link between the Oxford University/AstraZeneca COVID-19 and a mostly mild and Share XStudy links AstraZeneca COVID-19 shot to bleeding disorder ITPhttps://pharmaphorum.com/news/study-links-astrazeneca-covid-19-shot-to-bleeding-disorder-itp/
ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence dataAstraZeneca has thrown down the gauntlet to AbbVie and Johnson & Johnson with new data for Calquence in Share XASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence datahttps://pharmaphorum.com/news/asco21-az-seeks-to-supplant-imbruvica-in-cll-with-new-calquence-data/
MorphoSys offers $1.7bn for Constellation, but investors see starsShares in German biotech MorphoSys have gone on the slide after it announced a $1.7 billion deal to Share XMorphoSys offers $1.7bn for Constellation, but investors see starshttps://pharmaphorum.com/news/morphosys-offers-1-7bn-for-constellation-but-investors-see-stars/
Sanofi eyes 2022 filing for haemophilia drug fitusiran, despite safety issueSanofi’s much anticipated drug for both haemophilia A and B – fitusiran – could be filed in 2022 Share XSanofi eyes 2022 filing for haemophilia drug fitusiran, despite safety issuehttps://pharmaphorum.com/news/sanofi-eyes-2022-filing-for-haemophilia-drug-fitusiran-despite-safety-issue/
bluebird bio ‘baffled’ after NICE rejects beta-thalassaemia gene therapyIt’s back to the drawing board for bluebird bio and its discussions with NICE, which has rejected its Share Xbluebird bio ‘baffled’ after NICE rejects beta-thalassaemia gene therapyhttps://pharmaphorum.com/news/bluebird-bio-baffled-after-nice-rejects/
NICE reverses stance on Celgene’s Revlimid for myeloma maintenanceNHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after Share XNICE reverses stance on Celgene’s Revlimid for myeloma maintenancehttps://pharmaphorum.com/news/nice-reverses-view-of-celgenes-revlimid-for-myeloma-maintenance/
